KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Adaptive Biotechnologies (ADPT) Operating Income (2018 - 2025)

Adaptive Biotechnologies' Operating Income history spans 8 years, with the latest figure at -$12.8 million for Q4 2025.

  • For Q4 2025, Operating Income rose 62.25% year-over-year to -$12.8 million; the TTM value through Dec 2025 reached -$57.1 million, up 64.86%, while the annual FY2025 figure was -$57.1 million, 64.86% up from the prior year.
  • Operating Income for Q4 2025 was -$12.8 million at Adaptive Biotechnologies, down from $10.3 million in the prior quarter.
  • Across five years, Operating Income topped out at $10.3 million in Q3 2025 and bottomed at -$71.1 million in Q4 2023.
  • The 5-year median for Operating Income is -$47.6 million (2023), against an average of -$42.8 million.
  • The largest annual shift saw Operating Income tumbled 81.36% in 2023 before it skyrocketed 131.53% in 2025.
  • A 5-year view of Operating Income shows it stood at -$61.6 million in 2021, then soared by 36.38% to -$39.2 million in 2022, then crashed by 81.36% to -$71.1 million in 2023, then soared by 52.39% to -$33.8 million in 2024, then soared by 62.25% to -$12.8 million in 2025.
  • Per Business Quant, the three most recent readings for ADPT's Operating Income are -$12.8 million (Q4 2025), $10.3 million (Q3 2025), and -$25.0 million (Q2 2025).